Event

Digital Scholar Webinar: Breaking Down (Brick) Walls: Switching to Remote, Virtual, & Decentralized Clinical Trials

October 7, 2020 : 12:00pm - 1:00pm at Online Webinar
Register

Online Webinar

Event Details

In this 60-minute webinar, Dr. Tenaerts presents the work of the Clinical Trials Transformation Initiative (CTTI) and discusses two main topics regarding digital clinical trials: (1) moving ongoing trials to remote and (2) planning for decentralized trials.

At the conclusion of this webinar you will be able to

  • Recognize how the trials community has pivoted to virtual and remote visits for ongoing trials. Identify CTTI’s recommendations for digital health trials and decentralized clinical trials.

Speaker:

Pamela-Tenaerts.jpg#asset:6072

Dr. Pamela Tenaerts, M.D.

Pamela Tenaerts, MD, MBA is executive director at the Clinical Trials Transformation Initiative (CTTI) where she works closely with the Executive Committee to develop and implement strategies to accomplish the organization’s mission. She orchestrates efforts to effectively engage all interested stakeholders to improve the conduct of clinical trials. She is on the Board of Directors for the Society of Clinical Trials and a member of DIA’s Advisory Council North America and DiMe Society’s Scientific Advisory Board. Dr. Tenaerts is an independent director on the board of TRxADE Group, Inc. She practiced medicine in both the emergency department and in a private practice setting before embarking on a career in research. Dr. Tenaerts has obtained Six Sigma Green Belt certification.

Disclaimer: The presenter is an Employee of Duke University. Salary support comes from pooled membership fees of the Clinical Trials Transformation Initiative and from FDA Cooperative agreement and is an independent first of the board of TRxADE, inc.


NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.